Tags

Type your tag names separated by a space and hit enter

Histamine skin test reactivity following single and multiple doses of azelastine nasal spray in patients with seasonal allergic rhinitis.
Ann Allergy Asthma Immunol. 2003 Sep; 91(3):258-62.AA

Abstract

OBJECTIVE

To determine whether azelastine nasal spray suppresses the dermal response to epicutaneous histamine in allergic patients and the duration of suppression after azelastine use is discontinued.

METHODS

Seventy-eight patients with seasonal allergic rhinitis were entered into this randomized, double-blind, parallel-group, placebo-controlled study. Patients received either azelastine nasal spray (2 sprays per nostril twice daily) or placebo nasal spray for 14 days. Skin tests were performed 5 hours after the first dose of study drugs to determine the effect of a single dose of azelastine nasal spray on the wheal-and-flare response to histamine. At the end of the 14-day treatment period, skin tests were performed 5 hours after the last dose of study drugs and at 24-hour intervals thereafter, until each patient's wheal-and-flare response to histamine (1.0 and 5.0 mg/mL) returned to within 20% of baseline values.

RESULTS

A single dose of azelastine nasal spray did not significantly alter the wheal-and-flare response to histamine. The wheal response was within 20% of the baseline value in 82% and 88% (1.0 and 5.0 mg/mL of histamine, respectively) of the patients 5 hours after discontinuing 14 days of treatment with azelastine nasal spray. Wheal responses were within 20% of baseline values 48 hours after treatment was discontinued, whereas flare responses returned to within 20% of baseline within 48 hours in 92% of the patients.

CONCLUSIONS

Azelastine nasal spray should be discontinued for at least 48 hours before beginning allergy skin test procedures.

Authors+Show Affiliations

Colorado Allergy & Asthma Centers, PC, Denver, Colorado 80230, USA. ds.pearlman@coloradoallergy.comNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

14533657

Citation

Pearlman, David S., et al. "Histamine Skin Test Reactivity Following Single and Multiple Doses of Azelastine Nasal Spray in Patients With Seasonal Allergic Rhinitis." Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology, vol. 91, no. 3, 2003, pp. 258-62.
Pearlman DS, Grossman J, Meltzer EO. Histamine skin test reactivity following single and multiple doses of azelastine nasal spray in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2003;91(3):258-62.
Pearlman, D. S., Grossman, J., & Meltzer, E. O. (2003). Histamine skin test reactivity following single and multiple doses of azelastine nasal spray in patients with seasonal allergic rhinitis. Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology, 91(3), 258-62.
Pearlman DS, Grossman J, Meltzer EO. Histamine Skin Test Reactivity Following Single and Multiple Doses of Azelastine Nasal Spray in Patients With Seasonal Allergic Rhinitis. Ann Allergy Asthma Immunol. 2003;91(3):258-62. PubMed PMID: 14533657.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Histamine skin test reactivity following single and multiple doses of azelastine nasal spray in patients with seasonal allergic rhinitis. AU - Pearlman,David S, AU - Grossman,Jay, AU - Meltzer,Eli O, PY - 2003/10/10/pubmed PY - 2003/11/13/medline PY - 2003/10/10/entrez SP - 258 EP - 62 JF - Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology JO - Ann Allergy Asthma Immunol VL - 91 IS - 3 N2 - OBJECTIVE: To determine whether azelastine nasal spray suppresses the dermal response to epicutaneous histamine in allergic patients and the duration of suppression after azelastine use is discontinued. METHODS: Seventy-eight patients with seasonal allergic rhinitis were entered into this randomized, double-blind, parallel-group, placebo-controlled study. Patients received either azelastine nasal spray (2 sprays per nostril twice daily) or placebo nasal spray for 14 days. Skin tests were performed 5 hours after the first dose of study drugs to determine the effect of a single dose of azelastine nasal spray on the wheal-and-flare response to histamine. At the end of the 14-day treatment period, skin tests were performed 5 hours after the last dose of study drugs and at 24-hour intervals thereafter, until each patient's wheal-and-flare response to histamine (1.0 and 5.0 mg/mL) returned to within 20% of baseline values. RESULTS: A single dose of azelastine nasal spray did not significantly alter the wheal-and-flare response to histamine. The wheal response was within 20% of the baseline value in 82% and 88% (1.0 and 5.0 mg/mL of histamine, respectively) of the patients 5 hours after discontinuing 14 days of treatment with azelastine nasal spray. Wheal responses were within 20% of baseline values 48 hours after treatment was discontinued, whereas flare responses returned to within 20% of baseline within 48 hours in 92% of the patients. CONCLUSIONS: Azelastine nasal spray should be discontinued for at least 48 hours before beginning allergy skin test procedures. SN - 1081-1206 UR - https://www.unboundmedicine.com/medline/citation/14533657/Histamine_skin_test_reactivity_following_single_and_multiple_doses_of_azelastine_nasal_spray_in_patients_with_seasonal_allergic_rhinitis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1081-1206(10)63527-2 DB - PRIME DP - Unbound Medicine ER -